---
title: "Ocrevus (ocrelizumab) in multiple sclerosis: Clinical trials questions"
description: "Clinical trials questions on Ocrevus (ocrelizumab) in multiple sclerosis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results, Long-term data, and Patient experience. Questions: How much does Ocrevus reduce MS relapses vs Rebif (OPERA I and II)? Does Ocrevus slow MS disability progression vs Rebif (OPERA I and II)? Can Ocrevus improve disability (confirmed disability improvement) in relapsing MS? How much does Ocrevus reduce MS lesions on MRI compared with Rebif? 11 further questions follow. 15 questions quoted from 9 sources."
canonical: "https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/clinical-trials"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ocrevus (ocrelizumab) in multiple sclerosis: Clinical trials questions

Manufacturer: Genentech, Inc.  
Prescribing information: [Ocrevus](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf), [Ocrevus Zunovo](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf)

Questions that apply to every indication of Ocrevus are on [Ocrevus (ocrelizumab), all indications](https://www.evicenter.com/medical-information/ocrevus).

## Study results

<a id="ocrevus-opera-relapse-rate"></a>

### How much does Ocrevus reduce MS relapses vs Rebif (OPERA I and II)?

Applies to: Relapsing forms of multiple sclerosis in adults (OCREVUS intravenous, OPERA I and II)

> “OPERA I and II (RMS): Two randomized, double-blind, double-dummy, active comparator–controlled clinical trials of identical design vs Rebif in 1656 patients (OCREVUS: OPERA I [n=410], OPERA II [n=417]; Rebif: OPERA I [n=411], OPERA II [n=418]) with RMS treated for 96 weeks. Both studies included patients who had experienced ≥1 relapse within the prior year, or ≥2 relapses within the prior 2 years, and had an EDSS score between 0 and 5.5.<sup>1,3</sup>”

Source: [OCREVUS: Safety, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/safety.html#:~:text=OPERA%20I%20and%20II%20%28RMS%29%3A,EDSS%20score%20between%200%20and)

> “Controlled period primary endpoint<sup>1</sup>
>
> OPERA I
>
> 46%
>
> Relative reductions p<0.0001
> ARR with OCREVUS vs Rebif:
>
> 0.156 vs 0.292
>
> OPERA II
>
> 47%
>
> Relative reductions p<0.0001
> ARR with OCREVUS vs Rebif:
>
> 0.155 vs 0.290”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/efficacy.html#:~:text=Controlled%20period%20primary,0.155%20vs%200.290)

> “Proportion Relapse-free 
> 83% 
> 71% 
> 82% 
> 72%”

Source: [OCREVUS: OCREVUS \[IV\], page 19, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=19)

> “In Study 1, 410 patients were randomized to OCREVUS and 411 to REBIF; 11% of OCREVUS-treated and 
> 17% of REBIF-treated patients did not complete the 96-week double-blind treatment period.”

Source: [OCREVUS: OCREVUS \[IV\], page 19, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=19)

> “In Study 2, 417 patients were randomized to OCREVUS and 418 to REBIF; 14% of OCREVUS-treated and 
> 23% of REBIF-treated patients did not complete the 96-week double-blind treatment period.”

Source: [OCREVUS: OCREVUS \[IV\], page 19, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=19)

Note: The relapse-free proportions are from Table 6 of the OCREVUS Prescribing Information, in the order Study 1 OCREVUS, Study 1 REBIF, Study 2 OCREVUS, Study 2 REBIF; Studies 1 and 2 are OPERA I and II (same enrollment, 410 and 411, 417 and 418).

<a id="ocrevus-opera-disability-progression"></a>

### Does Ocrevus slow MS disability progression vs Rebif (OPERA I and II)?

Applies to: Relapsing forms of multiple sclerosis in adults (OCREVUS intravenous, OPERA I and II)

> “12-week CDP<sup>1</sup>
>
> 40%
>
> Risk reduction
>
> HR (95% CI): 0.60 (0.45, 0.81)
> p=0.0006
>
> 12-week CDP (proportion of patients)<sup>1</sup>
> Prespecified, pooled analysis:
> 9.8% OCREVUS vs 15.2% Rebif
>
> In the individual OPERA studies<sup>3</sup>:
> OPERA I: 7.6% OCREVUS vs 12.2% Rebif
> OPERA II: 10.6% OCREVUS vs 15.1% Rebif
>
> 24-week CDP<sup>3</sup>
>
> 40%
>
> Risk reduction
>
> HR (95% CI): 0.60 (0.43, 0.84)
> p=0.003
>
> 24-week CDP (proportion of patients)<sup>3</sup>
> Prespecified, pooled analysis:
> 7.6% OCREVUS vs 12% Rebif
>
> In the individual OPERA studies<sup>3</sup>:
> OPERA I: 5.9% OCREVUS vs 9.5% Rebif
> OPERA II: 7.9% OCREVUS vs 11.5% Rebif
>
> 48-week CDP vs Rebif (controlled period, post hoc analysis)<sup>4,5</sup>
>
> 57% risk reduction (proportion of patients: 3.2% OCREVUS vs 7.2% Rebif)
> Not prespecified to conclude statistical significance; these data only convey numerical trends”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/efficacy.html#:~:text=12%2Dweek,data%20only%20convey%20numerical%20trends)

> “Progression of disability was defined as an increase of 1 point or more from the baseline EDSS score 
> attributable to MS when the baseline EDSS score was 5.5 or less, or 0.5 points or more when the baseline EDSS 
> score was above 5.5. Disability progression was considered confirmed when the increase in the EDSS was 
> confirmed at a regularly scheduled visit 12 weeks after the initial documentation of neurological worsening. The 
> primary population for analysis of confirmed disability progression was the pooled population from Studies 1 
> and 2.”

Source: [OCREVUS: OCREVUS \[IV\], page 18, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=18)

> “<sup>1</sup> Defined as an increase of 1.0 point or more from the baseline Expanded Disability Status Scale (EDSS) score for patients with 
> baseline score of 5.5 or less, or 0.5 or more when the baseline score is greater than 5.5, Kaplan-Meier estimates at Week 96.”

Source: [OCREVUS: OCREVUS \[IV\], page 19, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=19)

Note: The pooled 24-week CDP proportion for Rebif is given as 12% on the efficacy page and as 12.2% on the Why Ocrelizumab page of the same site.

<a id="ocrevus-opera-disability-improvement"></a>

### Can Ocrevus improve disability (confirmed disability improvement) in relapsing MS?

Applies to: Relapsing forms of multiple sclerosis in adults (OCREVUS intravenous, OPERA I and II)

> “Significant difference in CDI vs Rebif (controlled period)<sup>3</sup>
> >20% of OCREVUS-treated patients showed CDI in OPERA I and II studies
>
> Confirmed disability improvement (CDI) was defined as a reduction from the baseline EDSS score of at least 1.0 point (or 0.5 points if the baseline EDSS score was >5.5) that was sustained for at least 12 weeks in patients with a baseline EDSS score of at least 2.0.
>
> Prespecified pooled analysis<sup>3</sup>
> 12-week CDI
>
> (proportion of patients)
>
> 33%
>
> DIFFERENCE
>
> p=0.02
>
> Pooled analysis:
> 20.7% OCREVUS vs 15.6% Rebif”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/efficacy.html#:~:text=Significant%20difference%20in%20CDI%20vs,20.7%25%20OCREVUS%20vs%2015.6%25%20Rebif)

<a id="ocrevus-opera-mri-lesions"></a>

### How much does Ocrevus reduce MS lesions on MRI compared with Rebif?

Applies to: Relapsing forms of multiple sclerosis in adults (OCREVUS intravenous, OPERA I and II)

> “Mean number of T1 Gd-enhancing lesions per MRI 
> 0.016 
> 0.286 
> 0.021 
> 0.416 
> Relative Reduction 
> 94% (p<0.0001) 
> 95% (p<0.0001)”

Source: [OCREVUS: OCREVUS \[IV\], page 19, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=19)

> “Mean number of new and/or enlarging T2 
> hyperintense lesions per MRI  
> 0.323 
> 1.413 
> 0.325 
> 1.904 
> Relative Reduction 
> 77% (p<0.0001) 
> 83% (p<0.0001)”

Source: [OCREVUS: OCREVUS \[IV\], page 19, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=19)

Note: Both rows are from Table 6 of the OCREVUS Prescribing Information, in the order Study 1 OCREVUS, Study 1 REBIF, Study 2 OCREVUS, Study 2 REBIF, measured over 96 weeks; Studies 1 and 2 are OPERA I and II.

<a id="ocrevus-opera-neda"></a>

### How many Ocrevus patients had no evidence of disease activity (OPERA I and II)?

Applies to: Relapsing forms of multiple sclerosis in adults (OCREVUS intravenous, OPERA I and II)

> “NEDA by Week 96 (post hoc analysis)
> No evidence of disease activity (NEDA) in the controlled period, including re-baselined analysis
> NEDA is the proportion of RMS patients with<sup>3</sup>:
> No protocol-defined relapses
> No 3-month or 6-month CDP
> No T1 Gd+ MRI activity
> No new or enlarging T2 lesions
>
> Controlled period NEDA<sup>9</sup>
> Pooled analysis
>
> 48%
> OCREVUS
> 		27%
> Rebif
>
> Weeks 0-96”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/efficacy.html#:~:text=NEDA%20by%20Week%2096%20%28post,Weeks%200%2D96)

> “The predefined secondary endpoint was not statistically significant, and it was considered nonconfirmatory because it fell below the break in the statistical hierarchy at change in Multiple Sclerosis Functional Composite Scale (MSFCS) score from baseline to Week 96<sup>3,10</sup>
> Exploratory result based on modified ITT population<sup>3,10</sup>”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/efficacy.html#:~:text=The%20predefined%20secondary%20endpoint%20was,result%20based%20on%20modified%20ITT)

This passage is in a collapsed section of the page; select: ASSESSMENT AND LIMITATIONS OF NEDA IN OPERA I AND II

> “Re-baselined NEDA<sup>9</sup>
> Pooled analysis
>
> 72%
> OCREVUS
> 		42%
> Rebif
>
> Weeks 24-96
> (re-baselined to 24 weeks)
>
> 82%
> OCREVUS
> 		57%
> Rebif
>
> Weeks 48-96
> (re-baselined to 48 weeks)”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/efficacy.html#:~:text=and%20disease%20activity.-,Re%2Dbaselined,%28re%2Dbaselined%20to%2048%20weeks%29)

> “During Weeks 48 to 96, the lower frequency of MRI scans compared with other time periods may have influenced the proportion of patients maintaining NEDA<sup>9</sup>”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/efficacy.html#:~:text=During%20Weeks%2048%20to%2096%2C,the%20proportion%20of%20patients%20maintaining)

On the page, select: ASSESSMENT AND LIMITATIONS OF RE-BASELINED NEDA IN OPERA I AND II

> “Conclusions from cross-trial comparisons are limited because of differences including comparators, patient populations, MRI techniques, frequency of assessments, analysis methods, and definitions of NEDA<sup>9</sup>”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/efficacy.html#:~:text=Conclusions%20from%20cross%2Dtrial%20comparisons%20are,analysis%20methods%2C%20and%20definitions%20of)

On the page, select: ASSESSMENT AND LIMITATIONS OF RE-BASELINED NEDA IN OPERA I AND II

<a id="ocrevus-oratorio-results"></a>

### How well does Ocrevus work in primary progressive MS (ORATORIO)?

Applies to: Primary progressive multiple sclerosis in adults (OCREVUS intravenous)

> “Study 3 was a randomized, double-blind, placebo-controlled clinical trial in patients with primary progressive 
> multiple sclerosis (PPMS). Patients were randomized 2:1 to receive either OCREVUS 600 mg or placebo as 
> two 300 mg intravenous infusions 2 weeks apart every 24 weeks for at least 120 weeks. Selection criteria 
> required a baseline EDSS of 3 to 6.5 and a score of 2 or greater for the EDSS pyramidal functional system due 
> to lower extremity findings. Neurological assessments were conducted every 12 weeks. An MRI scan was 
> obtained at baseline and at Weeks 24, 48, and 120.”

Source: [OCREVUS: OCREVUS \[IV\], page 20, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=20)

> “Study 3 randomized 488 patients to OCREVUS and 244 to placebo; 21% of OCREVUS-treated patients and 
> 34% of placebo-treated patients did not complete the trial.”

Source: [OCREVUS: OCREVUS \[IV\], page 20, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=20)

> “Proportion of patients with 12-week Confirmed Disability 
> Progression<sup>1</sup>  
> 32.9% 
> 39.3% 
> Risk reduction 
> 24%; p=0.0321”

Source: [OCREVUS: OCREVUS \[IV\], page 21, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=21)

> “12-WEEK CONFIRMED 
> DISABILITY PROGRESSION<sup>1,3</sup>
> 24-WEEK CONFIRMED 
> DISABILITY PROGRESSION<sup>1</sup>
> PRIMARY ENDPOINT
> HR (95% CI): 0.76 
> (0.59, 0.98); p=0.0321
> 24% RELATIVE RISK 
> REDUCTION
> HR (95% CI): 0.75 
> (0.58, 0.98); p=0.04
> 25% RELATIVE RISK 
> REDUCTION”

Source: [OCREVUS: Brochure, page 5, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-ppms-brochure.pdf#page=5)

> “In the overall population in Study 3, the proportion of patients with 20 percent worsening of the timed 25-foot 
> walk confirmed at 12 weeks was 49% in OCREVUS-treated patients compared to 59% in placebo-treated 
> patients (25% risk reduction).”

Source: [OCREVUS: OCREVUS \[IV\], page 22, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=22)

> “Mean change in volume of T2 lesions, from baseline to Week 120 
> (cm<sup>3</sup>)  
> -0.39 
> 0.79 
> p<0.0001”

Source: [OCREVUS: OCREVUS \[IV\], page 21, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=21)

> “29.6%
> 35.7%”

Source: [OCREVUS: Brochure, page 5, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-ppms-brochure.pdf#page=5)

Note: Study 3 of the OCREVUS Prescribing Information is ORATORIO (488 OCREVUS, 244 placebo). In its Table 7 the first value is OCREVUS and the second placebo. In the PPMS brochure passage, the first hazard ratio is for 12-week CDP (primary endpoint) and the second for 24-week CDP. In the brochure figure, 24-week CDP occurred in 29.6% of ocrelizumab-treated and 35.7% of placebo-treated patients.

<a id="ocrevus-oratorio-men-women"></a>

### Does Ocrevus work differently in men and women with primary progressive MS?

Applies to: Primary progressive multiple sclerosis in adults (OCREVUS intravenous)

> “In exploratory subgroup analyses of ORATORIO, the proportion of female patients with disability progression confirmed at 12 weeks after onset was similar in patients treated with OCREVUS and placebo, respectively (approximately 36% in each group). In male patients, the proportion of patients with disability progression confirmed at 12 weeks after onset was approximately 30% in OCREVUS-treated patients and 43% in placebo-treated patients. Clinical and MRI endpoints that generally favored OCREVUS numerically in the overall population, and that showed similar trends in both male and female patients, included annualized relapse rate, change in T2 lesion volume, and number of new or enlarging T2 lesions. ORATORIO was not powered to detect differences in these subgroups.<sup>1,8</sup>”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/efficacy.html#:~:text=In%20exploratory%20subgroup%20analyses%20of,to%20detect%20differences%20in%20these)

<a id="ocrevus-ohand-upper-limb"></a>

### Does Ocrevus slow disability in advanced primary progressive MS (OHAND)?

Applies to: Primary progressive multiple sclerosis in adults (OCREVUS intravenous)

> “Ocrelizumab is approved in patients with PPMS based on the Phase III ORATORIO pivotal trial<sup>1,3</sup>”

Source: [OCREVUS: Upper Extremity Function in PPMS, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/ohand.html#:~:text=Ocrelizumab%20is%20approved%20in%20patients,the%20Phase%20III%20ORATORIO%20pivotal)

> “OHAND evaluated preservation of function in patients with PPMS who were older and had more advanced disease compared to those studied in ORATORIO, with a focus on upper extremity (UE) function<sup>2</sup>”

Source: [OCREVUS: Upper Extremity Function in PPMS, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/ohand.html#:~:text=OHAND%20evaluated%20preservation%20of%20function,focus%20on%20upper%20extremity%20%28UE%29)

> “OHAND: Included patients with PPMS up to age 65 and with an EDSS up to 8.0<sup>2</sup>”

Source: [OCREVUS: Upper Extremity Function in PPMS, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/ohand.html#:~:text=OHAND%3A%20Included%20patients%20with%20PPMS,with%20an%20EDSS%20up%20to)

> “1:1 RANDOMIZATION
> Ocrelizumab
> Placebo
> Lasted until the last patient completed
> 144 weeks or until ≥340 confirmed progression
> events (9HPT or EDSS) were observed,
> whichever occurred earlier
> Ocrelizumab: n=505<sup>2</sup>
> Placebo: n=508<sup>2</sup>”

Source: [OCREVUS: Brochure, page 2, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-ppms-brochure.pdf#page=2)

> “A disability event was defined as the first occurrence of either<sup>4</sup>:
>
> 9HPT: ≥20% change in 9HPT time from baseline that was sustained on subsequent visits for at least 12 weeks
>
> OR
>
> EDSS: ≥1.0-point increase from a baseline EDSS score of ≤5.5 that was sustained on subsequent visits for at least 12 weeks or ≥0.5-point increase from a baseline EDSS score of >5.5 that was sustained on subsequent visits for at least 12 weeks
> OHAND primary endpoint: time to onset of 12-week composite CDP”

Source: [OCREVUS: Upper Extremity Function in PPMS, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/ohand.html#:~:text=A%20disability%20event%20was%20defined,onset%20of%2012%2Dweek%20composite%20CDP)

> “12-WEEK cCDP<sup>2</sup>
> PRIMARY ENDPOINT
> HR (95% CI): 0.7 
> (0.57, 0.86); p=0.0007
> 30% RISK 
> REDUCTION”

Source: [OCREVUS: Brochure, page 6, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-ppms-brochure.pdf#page=6)

> “Ocrelizumab
> (165)
> Placebo
> (205)
> Proportion of Patients, %
> 40
> 30
> 20
> 10
> 50
> 0
> 40.4%
> 32.7%”

Source: [OCREVUS: Brochure, page 6, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-ppms-brochure.pdf#page=6)

> “OHAND provided additional safety data consistent with the known profile for ocrelizumab<sup>2</sup>”

Source: [OCREVUS: Upper Extremity Function in PPMS, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/ohand.html#:~:text=OHAND%20provided%20additional%20safety%20data%20consistent%20with%20the%20known%20profile%20for)

> “OHAND was conducted during the COVID-19 pandemic, which may have influenced the incidence of AEs, serious AEs, and infections. The OHAND study enrolled older patients with higher levels of disability compared to those studied in ORATORIO. To contextualize these findings for OHAND, rates are presented both including and excluding COVID-19–related events.<sup>2</sup>”

Source: [OCREVUS: Upper Extremity Function in PPMS, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/ohand.html#:~:text=OHAND%20was%20conducted%20during%20the,both%20including%20and%20excluding%20COVID%2D19%E2%80%93related)

Note: In the brochure figure, 12-week cCDP occurred in 32.7% of ocrelizumab-treated patients (165) and 40.4% of placebo-treated patients (205); the extracted text lists the two values in reverse order. OHAND is not described in the OCREVUS Prescribing Information.

<a id="ocrevus-ocarina-ii-design"></a>

### How was Ocrevus Zunovo compared with Ocrevus IV (OCARINA II)?

Applies to: Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS ZUNOVO subcutaneous)

> “OCARINA II was a multicenter, randomized, open-label, parallel-arm trial conducted to evaluate the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of OCREVUS ZUNOVO compared with OCREVUS (ocrelizumab) [IV] based on the primary PK endpoint of AUC up to Week 12 post injection/infusion (AUCW1-12).<sup>1,2</sup>”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/efficacy.html#:~:text=OCARINA%20II%20was%20a%20multicenter%2C,to%20Week%2012%20post%20injection%2Finfusion)

> “Study 4 enrolled 236 patients (213 with RMS, 23 with PPMS), 18-65 years of age with an EDSS between 0 to 
> 6.5 at screening. The demographics were similar and baseline characteristics were balanced across the two 
> treatment groups. The mean age was 40 years in both groups. In the OCREVUS ZUNOVO group, 35% of patients 
> were male and the mean/median duration since MS diagnosis was 5.7/3.1 years, compared to 41% male and 
> 4.8/2.4 years in the ocrelizumab IV group.”

Source: [OCREVUS: OCREVUS ZUNOVO, page 21, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf#page=21)

> “FDA approval based on comparability in a PK bridge study<sup>1</sup>”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/efficacy.html#:~:text=FDA%20approval%20based%20on%20comparability%20in%20a%20PK%20bridge)

> “Non-inferior PK exposure was based on the first 12 weeks following administration of OCREVUS ZUNOVO (920 mg) vs OCREVUS [IV] (600 mg)<sup>1,2</sup>”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/efficacy.html#:~:text=Non%2Dinferior%20PK%20exposure%20was%20based,mg%29%20vs%20OCREVUS%20%5BIV%5D%20%28600)

> “Mean Cmax was reached after ~4 days, with 81% estimated bioavailability<sup>1</sup>”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/efficacy.html#:~:text=Mean%20Cmax%20was%20reached%20after%20~4%20days%2C%20with%2081%25%20estimated)

> “In Study 4, the differences in pharmacokinetic exposures following the administration of OCREVUS ZUNOVO 
> subcutaneously at 920 mg/23,000 units and ocrelizumab intravenously at 600 mg in MS patients were not 
> clinically significant.”

Source: [OCREVUS: OCREVUS ZUNOVO, page 14, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf#page=14)

Note: Study 4 of the OCREVUS ZUNOVO Prescribing Information is OCARINA II.

<a id="ocrevus-zunovo-b-cell-depletion"></a>

### Does Ocrevus Zunovo deplete B cells as much as Ocrevus IV?

Applies to: Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS ZUNOVO subcutaneous)

> “Treatment with OCREVUS ZUNOVO resulted in B-cell depletion levels comparable to OCREVUS [IV] as measured up to Week 24”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/efficacy.html#:~:text=Treatment%20with%20OCREVUS%20ZUNOVO%20resulted,measured%20up%20to%20Week%2024)

> “It is unclear to what extent B-cell levels associate with specific clinical outcomes in individual patients. The precise mechanisms through which OCREVUS [IV] exerts its therapeutic clinical effects in RMS and PPMS are not fully understood.”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/efficacy.html#:~:text=It%20is%20unclear%20to%20what,PPMS%20are%20not%20fully%20understood.)

<a id="ocrevus-zunovo-relapse-rate"></a>

### How many patients on Ocrevus Zunovo stayed relapse-free (OCARINA II)?

Applies to: Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS ZUNOVO subcutaneous)

> “OCREVUS ZUNOVO annualized relapse rate (ARR) results<sup>5</sup>”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/efficacy.html#:~:text=OCREVUS%20ZUNOVO%20annualized%20relapse%20rate%20%28ARR%29)

> “OCREVUS SC/SC 920 mg
> 97.2% (n=104/107)
> OCREVUS IV/SC 600 mg
> 97.2% (n=103/106)”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/efficacy.html#:~:text=OCREVUS%20SC%2FSC%20920%20mg,97.2%25%20%28n%3D103%2F106%29)

> “CCOD: September 12, 2024.<sup>5</sup>
> *Week 72 ARR data presented here are exploratory only. ARR is measured at Weeks 24, 48, and 96 as per protocol.<sup>5</sup>
> <sup>†</sup>Three patients (2.8%) in the OCREVUS IV/SC arm and two patients (1.9%) in the OCREVUS SC/SC arm had one relapse. One patient (0.9%) in the OCREVUS SC/SC arm had two relapses; unadjusted relapse rates per year were 0.02 and 0.03 in the IV/SC and SC/SC arms, respectively. The unadjusted ARR is the total number of relapses for all patients in the considered group divided by the total follow-up time.<sup>5</sup>”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/efficacy.html#:~:text=CCOD%3A%20September%2012%2C,divided%20by%20the%20total%20follow%2Dup)

> “Limitations
> The data presented is for exploratory purposes only
> These analyses were not controlled for Type 1 error and should not be used to draw definitive conclusions about the efficacy or safety of OCREVUS ZUNOVO”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo/efficacy.html#:~:text=The%20data%20presented%20is%20for,or%20safety%20of%20OCREVUS%20ZUNOVO)

> “One hundred eighteen patients 
> received OCREVUS ZUNOVO as their first dose and 118 patients received intravenous ocrelizumab for their 
> first dose (two separate 300 mg infusions at Weeks 0 and 2).”

Source: [OCREVUS: OCREVUS ZUNOVO, page 11, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf#page=11)

Note: OCARINA II was open label. The IV/SC arm received intravenous ocrelizumab for the first dose before OCREVUS ZUNOVO; the SC/SC arm received OCREVUS ZUNOVO throughout. On the efficacy page, the 97.2% values sit beneath a graphic of the proportion of patients free of relapses at Week 72.

<a id="ocrevus-chimes-black-hispanic"></a>

### How did Ocrevus work in Black and Hispanic people with MS (CHIMES study)?

Applies to: Black and Hispanic adults with relapsing multiple sclerosis (OCREVUS intravenous, CHIMES)

> “Prospective open-label, single-arm study of OCREVUS in Black and 
> Hispanic people living with RMS<sup>1,15</sup>”

Source: [OCREVUS: Brochure, page 4, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-chimes-study-results.pdf#page=4)

> “182 patients studied
> • 113 Black patients, 69 Hispanic patients
> • 18 to 65 years of age with relapsing MS
> • Enrolled at study centers across the US, including
> Puerto Rico, and 1 site in Kenya
> • All treated with OCREVUS<sup>a</sup>”

Source: [OCREVUS: Brochure, page 4, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-chimes-study-results.pdf#page=4)

> “NEDA IS THE PROPORTION OF RMS PATIENTS WITH<sup>1</sup>:
> NO  
> PROTOCOL-DEFINED 
> RELAPSES
> NO 6-MONTH 
> CDP
> NO T1 GD+ 
> MRI ACTIVITY
> NO NEW OR  
> ENLARGING T2 LESIONS
> CHIMES RESULTS: NEDA AT WEEK 48 (PRIMARY ANALYSIS)<sup>1</sup>
> NEDA data from this 1-year study have not yet been re-baselined.”

Source: [OCREVUS: Brochure, page 4, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-chimes-study-results.pdf#page=4)

> “50.5
> %
> (92 out of 182 total patients)
> 46
> %
> (52 out of 113)
> Black patients
> 58
> %
> (40 out of 69)
> Hispanic patients”

Source: [OCREVUS: Brochure, page 4, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-chimes-study-results.pdf#page=4)

> “• CHIMES is an ongoing, single-arm, open-label, Phase IV study in Black and Hispanic patients with the primary
> analysis conducted at Year 1
> • Because there is no comparator arm in the study, no comparisons can be made
> • OPERA and CHIMES are separate studies; no direct comparisons can be made
> • The OPERA Phase III clinical trials were conducted in RMS patients of any race/ethnicity while CHIMES is
> studying RMS patients who self-identify as Black or Hispanic
> • The CHIMES study and OPERA trials were conducted in different locations, at different timepoints, and using
> different methodologies”

Source: [OCREVUS: Brochure, page 4, captured 2026-11-12](https://www.ocrevus-hcp.com/content/dam/gene/ocrevus-hcp/pdfs/ocrevus-chimes-study-results.pdf#page=4)

Note: The three NEDA values at Week 48 are for all 182 patients, the 113 Black patients, and the 69 Hispanic patients.

## Long-term data

<a id="ocrevus-opera-long-term-extension"></a>

### What are the long-term results of Ocrevus in relapsing MS (10+ years)?

Applies to: Relapsing forms of multiple sclerosis in adults (OCREVUS intravenous, OPERA I and II)

> “ARR through 10+ years (controlled and open-label extension [OLE] periods)<sup>2</sup>
> ARRs observed in the OLE period were consistent with the controlled period<sup>2</sup>”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/efficacy.html#:~:text=ARR%20through%2010%2B%20years%20%28controlled,were%20consistent%20with%20the%20controlled)

> “Patients who received Rebif during the controlled period continued to receive Rebif during the open-label extension (OLE) screening period until their first infusion of OCREVUS<sup>6,15</sup>”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/efficacy.html#:~:text=Patients%20who%20received%20Rebif%20during,until%20their%20first%20infusion%20of)

> “Disability data through 10+ years<sup>6</sup>
> Time to onset of 24-week CDP (controlled and OLE periods)<sup>6,7</sup>
>
> In the controlled period, fewer OCREVUS patients experienced disability progression than those who started on Rebif”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/efficacy.html#:~:text=Disability%20data%20through%2010%2B,those%20who%20started%20on%20Rebif)

> “Patients in the OLE period successfully completed the controlled period and are subject to continued dropout; they may represent an enriched population. The endpoints measured were not prespecified or powered to conclude statistical significance; they only convey numerical trends. Conclusions regarding the treatment effect of OCREVUS cannot be drawn on the basis of OLE data. Measurements performed at intermediate timepoints were not prespecified in the statistical testing hierarchy and reflect numerical trends only.”

Source: [OCREVUS: Efficacy, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/efficacy.html#:~:text=Patients%20in%20the%20OLE%20period,and%20reflect%20numerical%20trends%20only.)

This passage is in a collapsed section of the page; select: OLE LIMITATIONS

Note: Year-by-year relapse and disability values from the extension appear on the page only as figures.

<a id="ocrevus-long-term-safety"></a>

### What are the long-term side effects of Ocrevus?

Applies to: Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS intravenous)

> “As of November 2023, 6155 patients have received OCREVUS in the all-exposure trial population, resulting in 30,396 patient-years (PY) of exposure<sup>5</sup>”

Source: [OCREVUS: Safety, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/safety.html#:~:text=As%20of%20November%202023%2C%206155,in%2030%2C396%20patient%2Dyears%20%28PY%29%20of)

> “In the OCREVUS all-exposure population, reported rates of AEs continue to be consistent with those seen during the controlled RMS and PPMS trials<sup>5</sup>”

Source: [OCREVUS: Safety, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/safety.html#:~:text=In%20the%20OCREVUS%20all%2Dexposure%20population%2C,the%20controlled%20RMS%20and%20PPMS)

> “Rate of serious infections (data as of November 2023)<sup>5</sup>
>
> 2.2
>
> /100 PY
>
> All-exposure population
>
> 1.7
>
> /100 PY
>
> All-RMS population
>
> 3.7
>
> /100 PY
>
> All-PPMS population”

Source: [OCREVUS: Safety, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/safety.html#:~:text=Rate%20of%20serious%20infections%20%28data,All%2DPPMS%20population)

> “Patients in the OLE period successfully completed the controlled period and are subject to continued dropout; they may represent an enriched population. Measured endpoints only convey numerical trends and were not or powered to conclude statistical significance. Conclusions regarding the treatment effect of OCREVUS cannot be drawn on the basis of OLE data”

Source: [OCREVUS: Safety, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus/safety.html#:~:text=Patients%20in%20the%20OLE%20period,the%20basis%20of%20OLE%20data)

This passage is in a collapsed section of the page; select: LIMITATIONS OF THE OPEN-LABEL, UNCONTROLLED STUDY PERIOD

Note: The all-exposure population includes patients from the controlled trials, their open-label extensions, and other ocrelizumab studies.

## Patient experience

<a id="ocrevus-zunovo-patient-preference"></a>

### Do patients prefer Ocrevus Zunovo injections or Ocrevus IV infusions?

Applies to: Relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults (OCREVUS ZUNOVO subcutaneous)

> “80.4%
>
> Preferred OCREVUS ZUNOVO method of delivery (SC) (n=82)
>
> 10.8%
>
> Preferred OCREVUS method of delivery (IV) (n=11)
>
> 8.8%
>
> Had no preference (n=9)”

Source: [OCREVUS: Patient-Reported Outcomes, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo-experience/patient-reported-outcomes.html#:~:text=80.4%25,Had%20no%20preference%20%28n%3D9%29)

> “PPQ data at Week 48 are described here. At Week 48, patients initially randomized to OCREVUS SC had received up to a maximum of 3 OCREVUS injections, while patients initially randomized to OCREVUS IV had received up to a maximum of 2 OCREVUS injections.<sup>2</sup>”

Source: [OCREVUS: Patient-Reported Outcomes, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo-experience/patient-reported-outcomes.html#:~:text=PPQ%20data%20at%20Week%2048,a%20maximum%20of%202%20OCREVUS)

> “PPQ limitations
> This was an exploratory endpoint 
> The impact of switch order and dosing frequency was not explored in the PPQ presented in OCARINA II
> The response options in the survey did not include all clinically relevant attributes that could have inhibited patients from carrying out a comprehensive trade-off analysis
> This data is reflective of the IV-SC arm only and did not explore a crossover design
> Questions were asked in a clinical trial setting, and responses may not be generalizable in the real-world setting”

Source: [OCREVUS: Patient-Reported Outcomes, captured 2026-11-12](https://www.ocrevus-hcp.com/ocrevus-zunovo-experience/patient-reported-outcomes.html#:~:text=PPQ%20limitations,generalizable%20in%20the%20real%2Dworld%20setting)

## Related pages
- [Medical information: Ocrevus (ocrelizumab): Multiple sclerosis](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis)
- [Indication](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/pharmacology)
- [Real-world evidence](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/storage-and-supply)
